Showing 2 results for Rasheed
Beri Tawfeq, Bizav Rasheed,
Volume 0, Issue 0 ( In Press 2024)
Abstract
Background and objectives: Rheumatoid arthritis (RA) is a long-term autoimmune disorder that primarily affects joints. The disease may also affect other parts of the body, including the skin, eyes, lungs, heart, nerves, and blood. Aim and objectives: To evaluate the effect of methotrexate on blood, liver, and renal parameters in Rheumatoid arthritis.
Methods: A six-month cross-sectional study was carried out on 60 consecutive patients of aged 19–70 years with diagnosed Rheumatoid arthritis on methotrexate treatment (10 mg) orally per week. A questionnaire form was taken from participants, and laboratory tests were done on renal and liver function and serological tests (complete blood count, erythrocyte sedimentation rate, glutamic pyruvic transaminase, a glutamic-oxaloacetic transaminase, creatinine, C-reactive protein, and rheumatoid factor as follow-up of drug taking).
Results: At the end of sample collection, age 19–70 years, female: male ratio 1.5:1, while the only significant differences in platelet level were between day one and fourteen of treatment with a P value < 0.05, Glutamic Pyruvic Transaminase (GPT) level was between day one and thirty with a P value < 0.05, and rheumatoid factor level was between day one, fourteen, and day one, thirty with P values of (0.01) and (0.04) respectively which were significant.
Conclusion: The recommended medication for all kinds of rheumatoid arthritis patients is methotrexate, which has had a notable impact on blood, liver, and kidney parameters. These characteristics could be used to track how well this medication works, how safe it is, and to follow up with patients.
Thivyah Prabha, Rasheed Khan, Shruthi Cn, Rathi Priya,
Volume 17, Issue 6 (Nov-Dec 2023)
Abstract
Background: Thyroid disorders are the most common cause of endocrine dysfunction among women of childbearing age. It is well-established that hypothyroid dysfunction can have significant adverse effects on pregnancy and fetal development. This study aimed to determine the prevalence of thyroid disorders among antenatal women and assess the maternal and fetal outcomes in pregnant women with hypothyroid disorders.
Methods: This prospective study was conducted in the antenatal clinic of the Department of Obstetrics and Gynaecology in association with the Biochemistry Department. After obtaining written informed consent, antenatal women aged 18-40 years were included in this study, regardless of their gestational period. Venous blood samples were collected from the antecubital vein, and thyrotropin, free triiodothyronine (free T3), and free thyroxine (free T4) levels were measured. Hypothyroid antenatal women were monitored throughout their pregnancies to evaluate maternal and fetal outcomes.
Results: Among the participants in this study, 149 antenatal women had thyroid disorders, with a prevalence rate of 12.6%. Subclinical hypothyroidism, overt hypothyroidism, subclinical hyperthyroidism, and overt hyperthyroidism were observed in 6.9%, 3.2%, 1.8%, and 0.7% of cases, respectively. Maternal complications included oligohydramnios (5.8%), preeclampsia (13.3%), and preterm delivery (5%), while fetal complications included low birth weight (20.8%), hyperbilirubinemia (9.1%), and neonatal intensive care unit (NICU) admissions (13.3%).
Conclusion: A high prevalence (12.6%) of thyroid disorders, particularly hypothyroidism (10.1%), among pregnant women, emphasizing the importance of routine thyroid testing for all antenatal individuals.
